Entheon Biomedical Corp. (CSE:ENBI)

Entheon Biomedical Income Statement

Financials in millions CAD. Fiscal year is December - November.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Nov 30, 2024	Nov 30, 2023	Nov 30, 2022	Nov 30, 2021	Nov 30, 2020
Revenue	-	0.25	0.19	-	-
Revenue Growth (YoY)	-	31.97%	-	-	-
Gross Profit	-	0.25	0.19	-	-
Selling, General & Admin	0.33	0.56	2.5	4.45	1.2
Research & Development	-	-	1.2	1.21	0.44
Operating Expenses	0.33	0.56	3.79	8.21	1.64
Operating Income	-0.33	-0.31	-3.6	-8.21	-1.64
Interest & Investment Income	0.02	0.01	0	0.01	0.01
Currency Exchange Gain (Loss)	-0	-0	0.02	0	-
Other Non Operating Income (Expenses)	-	0	0.25	-0	-2.74
EBT Excluding Unusual Items	-0.32	-0.3	-3.33	-8.2	-4.38
Gain (Loss) on Sale of Investments	-	0	-0.07	0.21	0.05
Gain (Loss) on Sale of Assets	-	-	1.34	-	-
Other Unusual Items	-	-	-	-	-0.05
Pretax Income	-0.32	-0.3	-2.06	-8	-4.38
Earnings From Continuing Operations	-0.32	-0.3	-2.06	-8	-4.38
Earnings From Discontinued Operations	-	-	-6.46	-0.89	-
Net Income	-0.32	-0.3	-8.52	-8.89	-4.38
Net Income to Common	-0.32	-0.3	-8.52	-8.89	-4.38
Shares Outstanding (Basic)	8	6	6	5	3
Shares Outstanding (Diluted)	8	6	6	5	3
Shares Change (YoY)	30.96%	-	8.85%	97.83%	543.78%
EPS (Basic)	-0.04	-0.05	-1.44	-1.64	-1.60
EPS (Diluted)	-0.04	-0.05	-1.44	-1.64	-1.60
Free Cash Flow	-0.36	-0.36	-1.95	-5.33	-2.85
Free Cash Flow Per Share	-0.05	-0.06	-0.33	-0.98	-1.04
Gross Margin	-	100.00%	100.00%	-	-
Operating Margin	-	-124.96%	-1898.18%	-	-
Profit Margin	-	-119.85%	-4492.23%	-	-
Free Cash Flow Margin	-	-143.79%	-1030.49%	-	-
EBITDA	-	-	-3.6	-8.18	-1.64
D&A For EBITDA	-	-	0	0.04	0
EBIT	-0.33	-0.31	-3.6	-8.21	-1.64
EBIT Margin	-	-124.96%	-	-	-
Revenue as Reported	-	0.25	0.19	-	-

Updated Mar 5, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.